Alzheimer’s disease (AD) causes gradual cognitive decline and dementia. Until recently, the definitive diagnosis of AD was based on autopsy assessments of brain amyloid-β plaques and tau neurofibrillary tangles, the defining biological features of AD. Biomarkers of amyloid-β and tau are vital for measuring AD pathology in living people and for differentiating between different neurodegenerative diseases. With the latest progress in AD research, accurate in-vivo diagnosis of AD is becoming increasingly crucial: before starting treatment with anti-amyloid therapies, it’s essential to determine if amyloid positivity is present.
In this video Joseph Therriault, PhD will discuss AD biomarkers and their use in clinical and research settings and explore future research areas for wider clinical practice use.
